About Avidity Biosciences
Avidity Biosciences is a publicly listed company based in San Diego (United States) founded in 2012, and was acquired by Novartis in October 2025. Antibody-siRNA complexes are developed for cancer treatment. Avidity Biosciences has raised $142.54 million across 7 funding rounds from investors including Lilly, Novartis and ARE. The company has 391 employees. Its chief executive, as recorded, is Sarah Boyce. Its website aviditybiosciences.com draws about 12 thousand monthly visits. Avidity Biosciences offers products and services including AOC Platform and Pipeline for DM1. Its focus areas include Life Sciences, Gene Therapy, RNA and siRNA. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Avidity Biosciences was founded in 2012 in San Diego, United States, within the biotechnology sector focused on oncology. Antibody-siRNA complexes, known as ARCs, are advanced to combine elements of antibody-drug conjugates and nucleic acid therapeutics. Targeted polymeric nanoparticles encapsulating siRNA payloads are created for delivery to specific tumor types. These nanoparticles are decorated with antibodies, proteins, peptides, or small molecules to enable binding to extracellular receptors and promote cellular uptake.
- Headquarters San Diego, United States
- Employees 391
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website aviditybiosciences.com
- Social LinkedIn X
- Acquired by Novartis (Oct 2025)
- Legal Name Avidity Biosciences, Inc.
- Annual Revenue$10.9 M (USD)13.99as on Dec 31, 2024
- Net Profit-$322.3 M (USD)-51.87as on Dec 31, 2024
- EBITDA-$376.16 M (USD)-61.1as on Dec 31, 2024
- Total Equity Funding$142.54M (USD)
in 7 rounds
- Latest Funding Round$400.21M (USD), Post-IPO
Mar 2024
- InvestorsLilly
& 18 more
- Employee Count391
- Acquired byNovartis
(Oct 2025)
Products & Services of Avidity Biosciences
Avidity Biosciences offers a comprehensive portfolio of products and services, including AOC Platform and Pipeline for DM1.
Platform combines antibodies and oligonucleotides for targeted disease treatment.
Develops treatments for myotonic dystrophy type 1 and related conditions.
Funding Insights of Avidity Biosciences
Avidity Biosciences has successfully raised a total of $142.54M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $400.21 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $142.54M
- Total Rounds 7
- Last Round Post-IPO — $400.21M
- First Round $9.07M
(Feb 2014)
- Investors Count 18
All 7 funding rounds of Avidity Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $400.21M | Post-IPO | – | – | – |
| Nov 2019 | $100.5M | Series C | – | RTW Investments | |
| Apr 2019 | $15M | Series B | – | Lilly | – |
| Oct 2018 | Series B | – | – | ||
| Jan 2017 | $17.97M | Series B | – | Takeda Ventures | |
| Jun 2014 | Series A | – | – | ||
| Feb 2014 | $9.07M | Series A | – | – | – |
19 investors in total: 19 institutional.
Investors in Avidity Biosciences
Avidity Biosciences has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Novartis and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
| takedaventures.com | ||||
Brace Pharma Capital is focused on investing in innovative therapies. | bracepharma.com | Atlanta, United States | ||
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Growth & expansion stage VC firm invesing in the US | moorevp.com | Encinitas, United States | ||
Tavistock Group is engaged in global diversified investments. | tavistock.com | |||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States |
Investor details for Avidity Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avidity Biosciences
217 people are tracked at Avidity Biosciences (125 in leadership, 6 in board & advisors, 86 in team); the tracked headcount is 391.
| Name | Role | Group |
|---|---|---|
Sarah Boyce | CEO & President | Leadership |
Michael Cochran | Director, Chemistry | Leadership |
Sharon Paige | Director, Clinical Development | Leadership |
Karen Mullin | Associate Director, Quality Assurance | Leadership |
Jason J. | VP US Commercial Operations | Leadership |
Marc Morris, MD JD | VP, Drug Safety & Pharmacovigilance | Leadership |
Cheryl Crook (Domier), PHR | Director, Human Resources | Leadership |
Brooke Bailey | Associate Director Clinical Operations | Leadership |
Sarang Rastogi | Senior Director, Clinical Developmental Lead - DMD | Leadership |
Shraddha Shah | Associate Director Clinical Data Management | Leadership |
Yoshi Inuzuka | Senior Director, Global Market Access | Leadership |
Haley R. | Director, Market Access Operations | Leadership |
Nirvana Moodley | Senior Director, Global Regulatory Affairs | Leadership |
Kelley Allison | Vice President, U.s. Market Access And Patient Services | Leadership |
Gautam Nayar | Senior Director | Leadership |
Ania W. | Associate Director - Accounting | Leadership |
Cameron Boehmer | Associate Director, Market Insights | Leadership |
Koji Takahashi | Vice President, Medical Affairs North America | Leadership |
Arthur A. Levin | Chief Scientific Officer | Leadership |
Teresa McCarthy | Chief Human Resources Officer | Leadership |
197 more people are available in the full profile.
Complete people profiles for Avidity Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Avidity Biosciences
Avidity Biosciences is a publicly listed company on the NASDAQ with ticker symbol RNA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Jun 2020
- Listed onNASDAQ: RNA
- Listed entityAvidity Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS04965N1046
- Share price$7.75 (-5.6% on the day) · 2026-10-13
- Market capitalisation$172.6M
- Volume (last session)237,187
Financials of Avidity Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $10.9M | -$322.3M | -$376.2M |
| 2023 | $9.6M | -$212.2M | -$233.5M |
| 2022 | $9.2M | -$174.0M | -$177.5M |
| 2021 | $9.3M | -$118.0M | -$117.4M |
| 2020 | $6.8M | -$44.4M | -$43.9M |
Detailed financial statements for Avidity Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Avidity Biosciences
5 dated milestones of Avidity Biosciences across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Avidity Biosciences is founded.
- Funding First funding round of $9.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $400.2M.
- Exit Acquired by Novartis.
Competitors of Avidity Biosciences
Avidity Biosciences has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Avidity Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Avidity Biosciences
The website of Avidity Biosciences (aviditybiosciences.com) receives about 11.7K visits a month and ranks #1,815,056 among all websites worldwide, #2,475 in Biotechnology and Pharmaceuticals.
- Monthly visits11.7K
▼ 9.9% vs previous month
- Unique visitors5.7K
per month
- Global rank#1,815,056
among all websites
- Category rank#2,475
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.9
- Average visit56 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Avidity Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sutrobio.com | 100% | 12.4K | #2,081,214 | View details | |
| fhi360.org | 60% | 113.6K | #368,995 | View details | |
| statnews.com | 40% | #28,251 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Avidity Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avidity Biosciences
Complete news archive for Avidity Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avidity Biosciences
Avidity Biosciences was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Avidity Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Sarah Boyce is the CEO of Avidity Biosciences, as recorded in our data.
Avidity Biosciences is a funded company, having raised a total of $142.54M across 7 funding rounds to date. The company's 1st funding round was a Series A of $9.07M, raised on Feb 2014.
Avidity Biosciences has 391 employees.
Annual revenue of Avidity Biosciences is $10.9M as on Dec 31, 2024.
Avidity Biosciences was founded in 2012 in San Diego, United States, within the biotechnology sector focused on oncology. Antibody-siRNA complexes, known as ARCs, are advanced to combine elements of antibody-drug conjugates and nucleic acid therapeutics. Targeted polymeric nanoparticles encapsulating siRNA payloads are created for delivery to specific tumor types. These nanoparticles are decorated with antibodies, proteins, peptides, or small molecules to enable binding to extracellular receptors and promote cellular uptake.
Avidity Biosciences's top competitors include C4 Therapeutics, Erasca and MiRagen.
Avidity Biosciences offers AOC Platform and Pipeline for DM1.
Yes, Avidity Biosciences is publicly traded on NASDAQ under the ticker symbol RNA.
Avidity Biosciences has 19 investors. Key investors include Lilly, Novartis, ARE, TPG, and RTW Investments.
Yes. Avidity Biosciences was acquired by Novartis in October 2025.